ADDF Grants $1.5M to Fund U.S. Arm of Phase 2a Trial for Vafidemstat in Alzheimer’s Patients

ADDF Grants $1.5M to Fund U.S. Arm of Phase 2a Trial for Vafidemstat in Alzheimer’s Patients
The Alzheimer's Drug Discovery Foundation (ADDF) has awarded $1.5 million to Oryzon Genomics to support expanding an ongoing Phase 2a trial assessing the potential of vafidemstat (ORY-2001) in patients with mild to moderate Alzheimer's disease to the United States. The double-blind, placebo-controlled trial (2017-004893-32), called ETHERAL, is currently recruiting patients at 17 sites across the U.K., France, and Spain. More than 90 patients have already been enrolled in the European arm of the trial, which is expected to include no more than 125 participants. The U.S. Food and Drug Administration recently approved an investigational new drug application for vafidemstat, clearing Oryzon to extend the trial to patients in the U.S. The new grant approved by ADDF's board of directors will support the enrollment of patients into the ETHERAL-US trial (NCT03867253). Oryzon is planning to recruit up to 30 patients from multiple sites across the U.S. for an expected total of at least 150 participants, including the European arm. Sites in Florida and New Jersey are now enrolling; information on contacts and locations
Subscribe or to access all post and page content.